NR 565 Week 5 Sample Paper

Adding Empagliflozin to Metformin in Type 2 Diabetes With Albuminuria: A Prescribing Decision, Its Monitoring Plan and Its Teaching Points

[Author Name]

College of Nursing, Chamberlain University

NR 565 Advanced Pharmacology Fundamentals

Week 5 Assignment

[Faculty Name]

August 11, 2026

Composite patient, written as a model document. Nothing here is prescribing guidance for any reader or any real person.

What this page is doingThe title names the drug, the patient population and the three things the paper delivers, so a reader knows before the first line that a decision is being defended rather than a class being described. Pharmacology papers lose credit when the title could sit on any paper about the same drug. The closing line refuses the one claim this genre must never make, which is that the document tells any reader what to prescribe.

The Patient and the Therapeutic Goal

The patient is a 58-year-old woman with type 2 diabetes of nine years' duration, seen in a primary care clinic for routine follow-up. Her glycated hemoglobin is 8.6 percent, up from 7.8 percent twelve months ago, on metformin extended release 1,000 mg twice daily, which she takes reliably. Her estimated glomerular filtration rate is 52 mL/min/1.73 m2, down from 61 two years ago, and her urine albumin-to-creatinine ratio is 340 mg/g on two separate specimens three months apart. Blood pressure is 138/84 mm Hg on lisinopril 20 mg daily, body mass index is 32.4, and potassium is 4.4 mmol/L. She has never had ketoacidosis, a genital fungal infection or a hypoglycemic event.

Three goals govern the decision, and they are not equally weighted. The first is slowing kidney disease: an albumin-to-creatinine ratio above 300 mg/g with a falling filtration rate is the dominant prognostic feature in this record, and it outranks the glycated hemoglobin number by itself. The second is bringing that value toward an individualized target near 7 percent without introducing hypoglycemia, since she drives for work and lives alone. The third is avoiding further weight gain. Success at three months means a glycated hemoglobin falling toward 7.5 percent with no hypoglycemia; success at six months means an albumin-to-creatinine ratio measurably lower than 340 mg/g and a filtration rate that has stabilized after any early dip.

What this page is doingThe goals are ranked, not listed. Saying that the albumin-to-creatinine ratio outranks the glycated hemoglobin sets the criterion the whole defense will be judged against, which is what lets the next sheet reject a faster glucose lowering drug without contradiction. The measurable targets at three and six months mean the plan can be shown right or wrong later. Constraints that shape prescribing, such as driving for work and living alone, are stated as facts here so they can be used as reasons later.

Defending the Choice: Empagliflozin 10 mg Daily, Added to Metformin

Empagliflozin blocks sodium-glucose cotransporter 2 in the proximal convoluted tubule, where roughly 90 percent of filtered glucose is normally reabsorbed. Blockade lowers the renal threshold for glucose, produces deliberate glycosuria of about 60 to 80 g per day, and reduces plasma glucose by a route that does not require insulin secretion, so the agent carries little intrinsic hypoglycemia risk. The accompanying natriuresis and osmotic diuresis lower systolic pressure by roughly 3 to 5 mm Hg and produce modest weight loss of 2 to 3 kg, both of which serve this patient's secondary goals. Expected glycated hemoglobin reduction is roughly 0.5 to 0.8 percentage points at her filtration rate, which is smaller than a sulfonylurea would deliver in the first months.

The kidney argument is what settles the choice. Increased sodium delivery to the macula densa restores tubuloglomerular feedback, constricts the afferent arteriole and lowers intraglomerular pressure, which is the hemodynamic reason this class slows albuminuria progression rather than merely tracking glucose. Cardiovascular and kidney outcome evidence for the class, beginning with the empagliflozin cardiovascular outcome trial, supports reduced cardiovascular death and reduced progression of kidney disease in patients who resemble this one, and current diabetes and kidney guideline statements place this class alongside metformin for people with type 2 diabetes and albuminuric chronic kidney disease. At a filtration rate of 52 mL/min/1.73 m2 she sits well above the thresholds in current labeling for starting the drug.

Two alternatives were considered and set aside for stated reasons. Glipizide would lower the glycated hemoglobin faster and cost less, but it works by forcing insulin secretion, which brings hypoglycemia risk to a woman who drives for work and lives alone, adds weight, offers no kidney or cardiovascular protection, and loses effect as beta cell function declines. Sitagliptin is well tolerated and weight neutral, but its glycemic effect is modest, it requires dose reduction as filtration falls, and it does not slow albuminuria. A glucagon-like peptide-1 receptor agonist was a genuine competitor and would have been the stronger choice had weight reduction been the leading goal, but it means an injection, higher out-of-pocket cost and gastrointestinal side effects that this patient asked to avoid.

What this page is doingMechanism comes before evidence, and evidence before comparison, because each move depends on the one before it. The transporter, the site and the insulin independent route explain the low hypoglycemia risk that the ranked goals demanded. The rejected alternatives are dismissed on the patient's own criteria rather than on general dislike, and one competitor is conceded as reasonable, which reads as judgment rather than advocacy. Naming a smaller glucose lowering effect out loud is a strength, since the defense does not depend on hiding it.

Monitoring: Baseline Values, Intervals and Thresholds

Baseline values are already on file and are the comparison the plan depends on: filtration rate 52 mL/min/1.73 m2, albumin-to-creatinine ratio 340 mg/g, potassium 4.4 mmol/L, glycated hemoglobin 8.6 percent, weight 87 kg, blood pressure 138/84 mm Hg. A basic metabolic panel is repeated two to four weeks after the first dose. A filtration rate dip of roughly 3 to 5 mL/min/1.73 m2 at that visit is expected, is hemodynamic rather than injurious, and reverses on withdrawal; it is not a reason to stop the drug. A fall greater than 30 percent from baseline, a rise in potassium above 5.5 mmol/L, or symptomatic orthostatic change would prompt review of the whole regimen rather than of one agent.

Longer intervals carry the outcome measures. The glycated hemoglobin is repeated at three months against the 7.5 percent interim goal, and the albumin-to-creatinine ratio at three to six months, since falling albuminuria is the signal that the kidney benefit is being realized in this patient rather than in a trial population. Weight and blood pressure are recorded at every visit, because both are expected to fall slightly and an unexpected rise argues for reassessing adherence. Between visits the plan names what she reports and when: genital itching or discharge, dysuria, lightheadedness on standing, and any illness with vomiting or reduced intake. Blood ketone testing is arranged for use during illness with persistent nausea or abdominal pain.

What this page is doingMonitoring is written as numbers with intervals attached, which is the difference between a plan and a promise to watch closely. Baseline values are restated so every later result has a comparison. The expected early filtration dip is named in advance along with the threshold that would change the plan, which shows the writer knows the normal course of the drug and will not stop it for a predictable finding. Outcome measures are separated from safety measures rather than mixed together.

Interactions, Cautions and Patient Teaching

Interaction review starts with her current list. Lisinopril and empagliflozin both lower blood pressure and both act on renal hemodynamics, so the combination is intended but calls for the orthostatic check above; the pairing does not raise potassium, and the sodium loss tends to offset the potassium retention the angiotensin converting enzyme inhibitor produces. Metformin has no pharmacokinetic interaction with this agent and continues unchanged. If a loop or thiazide diuretic were added later, additive volume depletion would become the leading hazard. Insulin or a sulfonylurea added to the regimen would carry real hypoglycemia risk and would need a dose reduction at the time it was started. Rifampin and other uridine glucuronosyltransferase inducers lower empagliflozin exposure.

Cautions and stopping rules belong in the record before the first dose. The drug is not appropriate in type 1 diabetes or after prior ketoacidosis, and it is stopped in pregnancy and while breastfeeding. Recurrent genital mycotic infection and prior necrotizing fasciitis of the perineum are cautions rather than paperwork; regulators have published safety communications on both ketoacidosis at near-normal glucose values and on that perineal infection. The drug is withheld during prolonged fasting, during acute illness with poor oral intake, and for several days before planned surgery, since these are the settings in which euglycemic ketoacidosis has been reported. Volume-depleted or acutely unwell patients are corrected before the drug is resumed.

Teaching was delivered in plain language and returned by teach-back. She takes the tablet each morning, with or without food, and continues metformin unchanged. Glucose will appear in her urine because that is how the drug works, so urine glucose strips are no longer meaningful for her and home fingerstick or sensor readings are used instead. She drinks to thirst and does not restrict fluids. She holds the drug and calls the clinic if she cannot keep food or fluids down for more than a day, if she is fasting for a procedure, or if she has nausea with abdominal pain and deep rapid breathing even when her glucose reads normal. She reports genital itching, discharge, or pain, swelling or redness between the genitals and the rectum with fever the same day.

What this page is doingInteractions are worked through the patient's actual medication list first, then extended to agents she might be given later, which keeps the section from becoming a generic list copied from a reference book. The cautions carry the regulatory safety warnings that belong to this class. Teaching is written in the words the patient heard and is anchored to teach-back, and each instruction ties to a mechanism already established, including the urine glucose point that follows directly from how the drug works.

References

American Diabetes Association Professional Practice Committee. (2025). Standards of care in diabetes-2025. Diabetes Care, 48(Suppl. 1). https://professional.diabetes.org/standards-of-care

Burchum, J. R., & Rosenthal, L. D. (2022). Lehne's pharmacotherapeutics for advanced practice nurses and physician assistants (3rd ed.). Elsevier.

Centers for Disease Control and Prevention. (2024). National diabetes statistics report. U.S. Department of Health and Human Services. https://www.cdc.gov/diabetes/

Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. (2022). KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney International, 102(5S), S1-S127. https://kdigo.org/guidelines/diabetes-ckd/

U.S. Food and Drug Administration. (2015). FDA drug safety communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. https://www.fda.gov/drugs/drug-safety-and-availability

Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. The New England Journal of Medicine, 373(22), 2117-2128. https://doi.org/10.1056/NEJMoa1504720

How this NR 565 Week 5 example is structured

In many sections this week asks for a drug therapy paper, meaning one patient, one prescribing decision, and a defense of that decision against the alternatives; your classroom's instructions decide the exact form, so read the week's assignment page, the rubric and any template before borrowing a structure. This NR 565 Week 5 example is ordered the way a prescribing decision is actually made. The first sheet fixes the therapeutic goal and the constraints the patient brings to it. The second argues the choice on mechanism, on outcome evidence and against two rejected alternatives. The third sets monitoring as baseline values, intervals and thresholds rather than as a promise to watch. The last handles interactions, cautions and what the patient is taught. The patient is a composite.

NR 565 Week 5 questions, answered

What does NR 565 Week 5 usually ask for?

In many sections this week asks for a drug therapy paper built on a patient scenario: name the choice, defend it on mechanism and evidence, then give monitoring, interactions and teaching. Your classroom's instructions decide the exact form and the required sections, so read the week's assignment page and rubric before you settle on a structure.

How do I defend a drug choice without sounding like a drug handbook?

Rank the goals for your patient first, then let the ranking do the rejecting. A handbook lists properties; a defense shows why one property mattered more than another for this person. Concede the strongest alternative and say what would have changed your decision. That single move separates graduate prescribing reasoning from a summary of a package insert.

What counts as a real monitoring plan?

Baseline values, named intervals, and thresholds that trigger a specific action. Write which laboratory value is repeated, when, and what result would change the drug or the dose. Separate safety monitoring from outcome monitoring, and name the expected findings that should not cause alarm, so the plan proves you know how the drug behaves over time.

Write yours, or have the desk draft it

This paper is an original model document written by our desk, not a submitted student paper and not an official Chamberlain University document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.

NR 565 Week 5: sample paper, in real form